OMCL Stock Recent News
OMCL LATEST HEADLINES
Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the BofA Securities 2024 Health Care Conference.
Omnicell (OMCL) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.39 per share a year ago.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the virtual KeyBanc Annual Life Sciences & MedTech Investor Forum.
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.
Revenues decreased in 2023 and will continue declining in 2024 as healthcare centers are reducing their capital investments due to increased operating costs. Profit margins decreased significantly in recent quarters as a consequence of weak volumes. Recent workforce reductions should stabilize margins in the short term, and high accounts receivable should provide strong cash from operations in the coming quarters.
Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.
Omnicell, Inc. (OMCL) Q4 2023 Earnings Call Transcript
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Fourth Quarter and Full Year 2023 Financial Results on February 8, 2024.
Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.